ARGX vs. GH: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and GH, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ARGX dominates in value with a market cap of 35.72 billion USD, eclipsing GH’s 4.60 billion USD by roughly 7.77×.
GH carries a higher beta at 1.49, indicating it’s more sensitive to market moves, while ARGX remains steadier at 0.17.
ARGX trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while GH remains a standard domestic listing.
| Symbol | ARGX | GH |
|---|---|---|
| Company Name | argenx SE | Guardant Health, Inc. |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Diagnostics & Research |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Dr. Helmy Eltoukhy Ph.D. |
| Price | 584.95 USD | 37.09 USD |
| Market Cap | 35.72 billion USD | 4.60 billion USD |
| Beta | 0.17 | 1.49 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 18, 2017 | October 4, 2018 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and GH over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and GH based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- GH shows a negative P/E of -11.03, highlighting a year of losses, whereas ARGX at 51.08 trades on solid profitability.
- GH carries a sub-zero price-to-book ratio of -18.32, indicating negative equity. In contrast, ARGX (P/B 7.75) has positive book value.
- ARGX and GH both consumed more free cash flow than they generated last year—P/FCF of -455.95 and -15.07, respectively—highlighting persistent liquidity pressure.
| Symbol | ARGX | GH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.08 | -11.03 |
| Forward PEG Ratio (TTM) | 1.35 | 0.46 |
| Price-to-Sales Ratio (P/S, TTM) | 16.50 | 5.94 |
| Price-to-Book Ratio (P/B, TTM) | 7.75 | -18.32 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -455.95 | -15.07 |
| EV-to-EBITDA (TTM) | 4572.56 | -13.08 |
| EV-to-Sales (TTM) | 15.84 | 6.72 |
| EV-to-Free Cash Flow (TTM) | -437.78 | -17.07 |
Dividend Comparison
Neither ARGX nor GH currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ARGX | GH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and GH, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- GH has negative equity (debt-to-equity ratio -5.21), suggesting asset shortfalls, whereas ARGX at 0.01 preserves healthier equity coverage.
- GH carries a debt-to-assets ratio of 0.97, suggesting substantial asset funding via debt, while ARGX at 0.01 opts for a more conservative financing structure.
- Both ARGX and GH report negative interest coverage ratios (-20.85, -166.83), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
| Symbol | ARGX | GH |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 4.11 |
| Quick Ratio (TTM) | 6.68 | 3.76 |
| Debt-to-Equity Ratio (TTM) | 0.01 | -5.21 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.97 |
| Interest Coverage Ratio (TTM) | -20.85 | -166.83 |